{
    "2021-10-28": [
        [
            {
                "time": "2023-10-25",
                "original_text": "What Investors Should Pay Attention to in AbbVie's Q3 Earnings Report",
                "features": {
                    "keywords": [
                        "Q3 earnings",
                        "AbbVie",
                        "investors"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-26",
                "original_text": "Should Investors Worry About AbbVie?",
                "features": {
                    "keywords": [
                        "Investors",
                        "Worry",
                        "AbbVie"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-27",
                "original_text": "AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "ABBV-951",
                        "Phase 3 Trial",
                        "Parkinson's Disease",
                        "Motor Fluctuations"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "neurology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}